Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Puma's (PBYI) alisertib receives the Orphan Drug designation from the FDA for treating patients with small cell lung cancer.

Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC

LOS ANGELES--(BUSINESS WIRE)--The FDA has granted Orphan Drug Designation to Puma Biotechnology's drug candidate alisertib for the treatment of small cell lung cancer.

Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO of Puma Biotechnology, will present a corporate update at the H.C. Wainwright Global Investment Conference beginning on 9/11/23.

Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference

LOS ANGELES--(BUSINESS WIRE)--Puma has been notified by the FDA that its IND has been reviewed, and Puma can proceed with clinical development of alisertib monotherapy for SCLC.

Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer

Puma Biotechnology (PBYI) beats second-quarter earnings and sales estimates. Stock rises in after-hours.

Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - Chairman, President and CEO Maximo Nougues - CFO Jeff Ludwig - CCO Conference Call Participants Ed White - H.C. Wainwright Divya Rao - TD Cowen and Company Alex Hammond - Bank of America Operator Good afternoon.

Puma Biotechnology, Inc. (PBYI) Q2 2023 Earnings Call Transcript

Puma Biotech (PBYI) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.21 per share a year ago.

Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its 2Q'23 earnings release on Aug. 3 and hosted a call at 4:30 pm ET to discuss results.

Puma Biotechnology Reports Second Quarter Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue operating results for 2Q-2023 on Aug. 3 and follow with a conference call at 1:30 pm PT.

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results

Genmab - ADR

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Puma Biotech (PBYI) and Genmab A/S Sponsored ADR (GMAB). But which of these two stocks is more attractive to value investors?

PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?

Ligand Pharmaceuticals

Mesoblast

Vaxcyte

Protagonist Therapeutics

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND, MESO and PBYI well amid volatility.

5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2023, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 22,500 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity award.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES--(BUSINESS WIRE)--Biomarker findings from a P II study of alisertib+paclitaxel v. paclitaxel alone in met. HR+ and triple neg breast cancer were presented at ASCO 2023.

Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Bio-Techne

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Puma Biotech (PBYI) and Techne (TECH). But which of these two companies is the best option for those looking for undervalued stocks?

PBYI or TECH: Which Is the Better Value Stock Right Now?

Puma Biotechnology (PBYI), a top-ranked stock, has a promising development candidate, alisertib. Its only marketed product, Nerlynx (neratinib), is witnessing improving demand trends in the United States.

Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Puma Biotech (PBYI) or Techne (TECH). But which of these two companies is the best option for those looking for undervalued stocks?

PBYI vs. TECH: Which Stock Is the Better Value Option?

Puma Biotechnology (PBYI) earnings and sales beat estimates in Q1. Stock rises in after-hours.

Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Rise Y/Y

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, Investor Relations Alan Auerbach - Chairman, President and CEO Maximo Nougues - Chief Financial Officer Jeff Ludwig - Chief Commercial Officer Conference Call Participants Ed White - H.C. Wainwright Divya Rao - TD Cowen Operator Good afternoon.

Puma Biotechnology, Inc. (PBYI) Q1 2023 Earnings Call Transcript

Puma Biotech (PBYI) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to loss of $0.08 per share a year ago.

Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates

LOS ANGELES--(BUSINESS WIRE)--On May 4, Puma Biotechnology reported its earnings results for the quarter ended March 31, 2023.

Puma Biotechnology Reports First Quarter Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its financial results for the first quarter of 2023 after market close, followed by a conference call, on May 4, 2023.

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Results of Puma's Phase II TBCRC041 trial of alisertib in patients with endocrine-resistant advanced breast cancer published online in JAMA Oncology.

Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology

Puma Biotechnology's (PBYI) Q4 2022 loss is wider than estimates, Revenues beat the same.

Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director of IR Alan Auerbach - CEO, President and Chairman Maximo Nougues - CFO Jeff Ludwig - Chief Commercial Officer Conference Call Participants Dave Rao - Cowen and Company Sahil Kazmi - B. Riley Securities Operator Good afternoon.

Puma Biotechnology, Inc. (PBYI) Q4 2022 Earnings Call Transcript

LOS ANGELES--(BUSINESS WIRE)--On March 2, 2023, Puma Biotechnology issued its financial results for the fourth quarter and full year ended Dec. 31, 2022.

News for Puma Biotechnology Stock (PBYI)